Anbio Biotechnology (NNNN) Common Equity (2023 - 2025)
Anbio Biotechnology has reported Common Equity over the past 3 years, most recently at $30.2 million for Q4 2025.
- Quarterly results put Common Equity at $30.2 million for Q4 2025, up 75.41% from a year ago — trailing twelve months through Dec 2025 was $30.2 million (up 75.41% YoY), and the annual figure for FY2025 was $30.2 million, up 75.41%.
- Common Equity for Q4 2025 was $30.2 million at Anbio Biotechnology, up from $17.2 million in the prior quarter.
- Over the last five years, Common Equity for NNNN hit a ceiling of $30.2 million in Q4 2025 and a floor of $14.8 million in Q4 2023.
- Median Common Equity over the past 3 years was $17.2 million (2024), compared with a mean of $20.7 million.
- Biggest five-year swings in Common Equity: rose 16.01% in 2024 and later surged 75.41% in 2025.
- Anbio Biotechnology's Common Equity stood at $14.8 million in 2023, then rose by 16.01% to $17.2 million in 2024, then surged by 75.41% to $30.2 million in 2025.
- The last three reported values for Common Equity were $30.2 million (Q4 2025), $17.2 million (Q4 2024), and $14.8 million (Q4 2023) per Business Quant data.